Drug Approval | December 05, 2022
Zydus receives final approval from USFDA for Estradiol Transdermal System
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of US $512 million for twelve months ending Sep 2022 according to IQVIA
Topiramate Extended-Release capsule had annual sales of US $68.8 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022)
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
The joint venture will help both the parties to further develop the high-margin service business
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
Subscribe To Our Newsletter & Stay Updated
